ImmunoGen, Inc. financial data

Industry
Pharmaceutical Preparations
Location
830 Winter St, Waltham, MA
State of incorporation
MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2023 - Nov 2, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 439 % -1.84%
Debt-to-equity 63.4 % -7.77%
Return On Equity -22.1 % +70.9%
Return On Assets -13.5 % +69.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 266M shares +20.6%
Common Stock, Shares, Outstanding 266M shares +20.5%
Entity Public Float 990M USD -24.7%
Common Stock, Value, Issued 2.44M USD +10.3%
Weighted Average Number of Shares Outstanding, Basic 273M shares +7.82%
Weighted Average Number of Shares Outstanding, Diluted 288M shares +13.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 208M USD +1.91%
Operating Income (Loss) -80.2M USD +59.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 29.6M USD
Income Tax Expense (Benefit) -1.17M USD
Net Income (Loss) Attributable to Parent -73.5M USD +63.4%
Earnings Per Share, Basic -0.31 USD/shares +62.7%
Earnings Per Share, Diluted 0.1 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 606M USD +95.6%
Inventory, Net 5.5M USD
Assets, Current 767M USD +132%
Property, Plant and Equipment, Net 4.43M USD -0.96%
Operating Lease, Right-of-Use Asset 8.34M USD -22.9%
Other Assets, Noncurrent 14.2M USD +8.08%
Assets 822M USD +129%
Accounts Payable, Current 24.9M USD +23.2%
Employee-related Liabilities, Current 15.2M USD +75.8%
Contract with Customer, Liability, Current 37.2M USD +147%
Liabilities, Current 135M USD +29.9%
Contract with Customer, Liability, Noncurrent 26.7M USD -31%
Operating Lease, Liability, Noncurrent 7.76M USD -36.5%
Other Liabilities, Noncurrent 2.8M USD +833%
Liabilities 261M USD +44.1%
Retained Earnings (Accumulated Deficit) -1.71B USD -4.5%
Stockholders' Equity Attributable to Parent 562M USD +215%
Liabilities and Equity 822M USD +129%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -73.7M USD -78.1%
Net Cash Provided by (Used in) Financing Activities 620K USD -98.2%
Net Cash Provided by (Used in) Investing Activities -209K USD +31.9%
Common Stock, Shares Authorized 600M shares 0%
Common Stock, Shares, Issued 266M shares +20.4%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -73.9M USD -79.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 606M USD +95.6%
Deferred Tax Assets, Valuation Allowance 334M USD -18.5%
Deferred Tax Assets, Gross 337M USD -18.4%
Operating Lease, Liability 15.2M USD -18.8%
Payments to Acquire Property, Plant, and Equipment 209K USD -31.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -240M USD -85.3%
Lessee, Operating Lease, Liability, to be Paid 18M USD -22.9%
Property, Plant and Equipment, Gross 35.7M USD +4.05%
Operating Lease, Liability, Current 4.46M USD +12%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.52M USD +0.35%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.5M USD +2.61%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.77M USD -39.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.54M USD +0.38%
Deferred Tax Assets, Operating Loss Carryforwards 115M USD -56.5%
Preferred Stock, Shares Issued 22K shares
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.43M USD -74.2%
Operating Lease, Payments 1.2M USD -14.3%
Preferred Stock, Shares Outstanding 22K shares
Depreciation, Depletion and Amortization 448K USD -5.29%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%